Just did a quick check of Accentia's website. Seems to describe a true cancer vaccine (tailored to each pt). I suspect that there might be a bit of data mining here as the Briefing piece only gave data for the Mantle Cell subset. I don't know whether or not there's an "investable" opportunity here - Seeing Bulletin Board scares me. I don't know which company has what rights to any income generated. With your prior cautions, I think I'll pass for now. However, I'd welcome any arguments that suggest it's worth consideration.
Ian
+++++++++++++++++++=
From: accentia.net
The BIOVAXID™ cancer immunotherapy stems from work begun in 1986 on development of a patient-specific follicular lymphoma (FL) vaccine. The cancer vaccine evokes the power of each patient's immune system and primes it to recognize and eliminate cancerous lymphoma cells, while sparing normal B-cells. In the vaccine's cancer target, indolent follicular B-cell lymphoma, the process is made possible by the presence of a hallmark surface antigen on the cancer cells that is not present in non-cancerous cells. By priming the immune system with this antigen in the form of an autologous vaccine, the vaccine induces an immune response against the cancerous cells and creates an immune memory. Because Accentia's BIOVAXID™ vaccine is derived from individual patient's cancerous cells, the vaccine is a true targeted, customized therapy. The vaccine's anti-tumor effect is different than non-targeted traditional therapy, as it arises from the immune system's defense cells' innate ability to selectively target foreign antigens. And importantly, the immune response triggered by the vaccine against the cancerous tissue is a natural disease-fighting mechanism and appears to be associated with minimal toxicity. |
